mk-1775
Small moleculeexperimental
Clinical trial activity
45 trials · 36 clinical orgs · 0 marketing orgs
Phase 1
27
Phase 2
23
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00648648)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Bile Duct Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Brenner Tumor · Phase 2
- Carcinoma · Early Phase 1
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Verrucous · Phase 2
- Central Nervous System Neoplasms · Phase 1/Phase 2
- Cerebrospinal Fluid · Phase 1
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Diffuse Intrinsic Pontine Glioma · Phase 1
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Glioblastoma · Phase 1
- Glioma · Phase 2
- Gliosarcoma · Phase 1
- Hamartoma · Phase 2
- Kidney Neoplasms · Phase 2
- Laryngeal Neoplasms · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 2
- Medulloblastoma · Phase 1/Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 1/Phase 2
- Neuroblastoma · Phase 1/Phase 2
- Ovarian Diseases · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pinealoma · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 2
- Rhabdomyosarcoma · Phase 1/Phase 2
- Skin Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Tongue Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
- Serine/threonine-protein kinase WEE1INHIBITOR
WEE1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1- Mol. weight
- 500.61 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1976040 ↗
Also known as
- azd1775
- azd1775
- azd1775
- azd 1775
- azd 1775
- azd-1775
- azd-1775
- azd-1775
- mk1775
- mk1775
- mk1775
- mk 1775
- mk-1775
- mk-1775
- mk-1775
- mk-1775
- mk-1775
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03284385 | Phase 2 | May 10, 2018 | National Cancer Institute (NCI), Yale University |
| NCT03313557 | Phase 1 | Oct 27, 2017 | AstraZeneca, Free University of Amsterdam, IQVIA |
| NCT03315091 | Phase 1 | Sep 29, 2017 | AstraZeneca, Free University of Amsterdam, IQVIA |
| NCT02791919 | Phase 1 | May 25, 2017 | National Cancer Institute (NCI) |
| NCT02666950 | Phase 2 | May 5, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03028766 | Phase 1 | May 1, 2017 | AstraZeneca, Cancer Research UK, University of Birmingham |
| NCT03012477 | Phase 2 | Jan 18, 2017 | AstraZeneca, Harvard University |
| NCT02937818 | Phase 2 | Nov 28, 2016 | AstraZeneca |
| NCT02546661 | Phase 1 | Oct 3, 2016 | AstraZeneca, SCRI Development Innovations, University of London |
| NCT02906059 | Phase 1 | Sep 1, 2016 | AstraZeneca, New York University |
| NCT02813135 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | Institut Gustave Roussy, National Cancer Institute, France |
| NCT02688907 | Phase 2 | Apr 1, 2016 | Sungkyunkwan University |
| NCT02659241 | Early Phase 1 (Phase 1) | Feb 1, 2016 | AstraZeneca, University of Texas at Houston |
| NCT02585973 | Phase 1 | Feb 1, 2016 | AstraZeneca, University of North Carolina at Chapel Hill |
| NCT02617277 | Phase 1 | Dec 18, 2015 | AstraZeneca, SCRI Development Innovations |
| NCT02610075 | Phase 1 | Dec 1, 2015 | AstraZeneca, SCRI Development Innovations |
| NCT02593019 | Phase 2 | Dec 1, 2015 | Sungkyunkwan University |
| NCT02576444 | Phase 2 | Nov 1, 2015 | Harvard University, Vanderbilt University, Yale University |
| NCT02513563 | Phase 2 | Sep 8, 2015 | University of South Florida |
| NCT02381548 | Phase 1 | Aug 18, 2015 | National Cancer Institute (NCI), University of Toronto |
Showing 20 of 45 trials
Page 1 / 3
Organizations
Research & Development (36)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 17 | 12 | 2 | 2014 |
| National Cancer Institute (NCI) | Government | 15 | 13 | 2 | 2012 |
| SCRI Development Innovations | For profit | 7 | 0 | 2 | 2014 |
| Merck | For profit | 5 | 4 | 2 | 2008 |
| Sungkyunkwan University | Academic/Hospital | 4 | 3 | 2 | 2015 |
| University of Toronto | Academic/Hospital | 4 | 0 | 2 | 2013 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Free University of Amsterdam | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Harvard University | Academic/Hospital | 2 | 1 | 1 | 2015 |
| IQVIA | For profit | 2 | 0 | 1 | 2017 |
| Yale University | Academic/Hospital | 2 | 1 | 1 | 2015 |
| American Society of Clinical Oncology | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Cancer Institute, France | Government | 1 | 0 | 1 | 2016 |
| NCC Hospital | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2010 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2015 |
36 organizations
Page 1 / 2